The Post-JUPITER trial era and the cost of preventive medicine.
Papadopoulos
Vassileios P
VP
D002097:C-Reactive Protein / Q000032:analysis; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000401:mortality*; D002423:Cause of Death; D005464:Fluorobenzenes / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D011315:Preventive Medicine / Q000191:economics*; D011743:Pyrimidines / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012015:Reference Standards; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000627:therapeutic use*
D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium; D002097:C-Reactive Protein